Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for Prevention of CINV in Pediatric Patients
NCT01362530Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Sep 2011; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01362530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362530.